PCSK9 and familial hyperaldosteronism: In fact, most of the patients with heterozygous FH who attained their LDL cholesterol treatment under secondary prevention settings and whose LDL cholesterol treatment target was below 70 mg/dL actually used PCSK9 inhibitors [73].